William Blair analyst Myles Minter has reiterated their bullish stance on NMRA stock, giving a Buy rating on April 28.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Myles Minter has given his Buy rating due to a combination of factors tied to Neumora’s pipeline and risk/reward setup. He views the upcoming KOASTAL-2 and KOASTAL-3 navacaprant readouts in major depressive disorder as high risk, but believes the market already reflects cautious expectations, creating an attractive upside if the data are positive.
Myles Minter’s rating is based on the belief that Neumora has multiple value-creating opportunities beyond navacaprant, including NMRA-511 in Alzheimer’s agitation and an NLRP3 inhibitor program with defined development milestones. With several potential “shots on goal,” a clear clinical timeline, and shares trading lower despite no major negative updates, he sees the current valuation as offering a compelling entry point for investors.
In another report released on April 28, Mizuho Securities also maintained a Buy rating on the stock with a $6.00 price target.